At Ventus, we are pioneering a unique approach to structure-based drug discovery to address biologically validated, but elusive, drug targets.  Using two platforms, we expand the set of targets amenable to small-molecule medicines including targets that have never been drugged and others for which existing chemical matter leaves significant room for improvement.

Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Our structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system. Advancing the next frontier for structure-based drug design to navigate elusive targets, in Montreal and Waltham, MA.